Conference Coverage

ASH: Novel GBT440 reduces sickle cells, improves hematologic parameters


 

AT ASH 2015

References

Dr. Thompson moderated the briefing in which Dr. Hemmaway presented the data.

The study is supported by Global Blood Therapeutics. Dr. Hemmaway had no relevant disclosures. Several co-investigators are employees of the company. Dr, Thompson had no disclosures relevant to the study.

Pages

Recommended Reading

What’s on tap at ASH 2015
MDedge Hematology and Oncology
ASH: Gene therapy reduces transfusion needs in beta-thalassemia major
MDedge Hematology and Oncology
ASH: Oral drug offers alternative to lifelong transfusions in sickle cell
MDedge Hematology and Oncology
VIDEO: RBCs have extended shelf life, randomized trial shows
MDedge Hematology and Oncology
ASH: HLA-identical sibling transplants “excellent” in eligble SCD patients
MDedge Hematology and Oncology
Device linked to anemia in blood donors
MDedge Hematology and Oncology
Risk of anaphylaxis with IV iron products
MDedge Hematology and Oncology
Team characterizes EMH niche
MDedge Hematology and Oncology
Study raises questions about iron dosing
MDedge Hematology and Oncology
FDA approves generic imatinib
MDedge Hematology and Oncology